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Tuberculosis (TB) remains a major cause of mortality and
morbidity worldwide. Currently, a third of the world’s
population is infected with Mycobacterium tuberculosis, the
causative agent of TB, and annually there are 10 million
new cases of clinical TB and approximately 2 million deaths
[1]. TB kills more individuals each year than any other
bacterial pathogen, and alarmingly, current control practices
have not been able to signiﬁcantly reduce the incidence of
the disease over the past 15 years [1]. The current vaccine
in use, Mycobacterium bovis bacille Calmette-Gu´ erin (BCG),
has been unable to limit the transmission of the disease, and
the problem is compounded by the HIV/AIDS pandemic
and the emergence of multidrug resistant strains of M.
tuberculosis including extensively drug-resistant strains in
multiple countries [2]. There is thus an urgent need to better
understand the host response to M. tuberculosis and develop
more eﬀective strategies to control TB.
This special issue contains original research reports
and review articles covering a number of aspects of TB
immunity. The ﬁrst series of articles focuses on immune
response to M. tuberculosis in humans. These studies range
from the expression of cytolytic mediators following BCG
vaccination in children (P. L. Semple et al.), control of
antigen presentation function (A. Aquino et al.), changes
in cellular makeup during postprimary TB (K. J. Welsh et
al.), and treatment of disseminated infection in immuno-
compromised individuals (A. A. Alangari et al.). The reviews
of S. Meraviglia et al. and H. Saiga et al. describe the role of
immune eﬀectors in mycobacterial infection, while articles
describing M. tuberculosis strain diversity (E. Nava-Agliluera
et al.), TB in myelitis (Y. Feng et al.), and humans T- and B-
cell responses to immunodominant mycobacterial antigens
(G. C. Macedo et al.) also form part of this special issue.
New insights on the interaction of M. tuberculosis with
the host are also provided in this special issue. The reviews of
M. Abebe et al., S. L. Sampson et al., and S. Ahmad describe
pathogenic mechanisms and virulence factors expressed by
M. tuberculosis, while the research articles of N. Sanarico et
al. and E. Giacomini et al. investigate the transcriptional and
cytokine response of host cells to M. tuberculosis infection.
Reviews on TB transcriptomics (C. R. Z´ arate-Blad´ es et
al.) and granuloma liquefaction (P.-J. Cardona) provide
furtherinsightintothediseaseprocessduringM.tuberculosis
infection.
The development of new vaccines is a major goal of
TB research programs, and this special issue contains a
number of articles investigating vaccine design and testing
in animal models. G. G. Guerrero and C. Locht report
on the use of recombinant antigens to boost BCG-induced
immunity, while C. Wang et al. and M. Okada et al. similarly
investigateprime-boostapproachestodevelopmoreeﬀective
TB vaccine regimens. The immune response following
vaccination with M. tuberculosis lipoproteins is described in
the article of C. Palma et al., and the use of cattle as a model
to study TB immunity is the focus of the review article of W.
R. Waters et al. The special issue closes with an overview of
biosensing technologies for detection of M. tuberculosis by Z.
Zhou et al.2 Clinical and Developmental Immunology
In conclusion, the aspects of immunity to M. tuberculosis
infection, host-pathogen interaction and vaccine develop-
mentcoveredinthisspecialissuemayleadtofutureadvances
in the treatment and control of TB.
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